Morning sickness drug reintroduced to US


The US Food and Drug Administration (FDA) has approved a drug for morning sickness, 30 years after it was originally removed from the market.

Diclegis (doxylamine succinate and pyridoxine hydrochloride), contains the same active ingredients as Benedictin, which was produced by Merrel Dow and withdrawn from the market in 1983 after a string of lawsuits claiming it caused birth defects.

Rather than fight the litigations, Merrel Dow voluntarily withdrew the product. However, Canadian company Duchesnay continued to market the drug in Canada, under the name Diclectin. Large scale studies have shown the drug to be safe for both mothers and foetuses, so Duchesnay has now decided to expand into the US by applying for approval of its long-release version.

The drug has been approved for use by pregnant women whose morning sickness cannot be controlled through dietary means, such as by eating smaller meals of bland food throughout the day.


Related Content

Chemistry World podcast - January 2014

15 January 2014 Podcast | Monthly

news image

This month, we examine the controversy surrounding the Turin shroud and explore the history of crystallography

Business roundup

26 February 2008 Business

news image

Industry news

Most Read

Quintuple bond activates small stable molecules

19 September 2014 Research

news image

Exotic complexes suggest route to synthetic feedstock

Computer simulations point to formamide as prebiotic intermediate in ‘Miller’ mixtures

16 September 2014 News and Analysis

news image

Electric field may have provided more than just energy for primordial chemistry

Most Commented

US genomics lead being lost to China

17 September 2014 News and Analysis

news image

NIH senior leaders are sounding the alarm bells, saying the US's pre-eminence in genomics research is under threat

The trouble with boycotts

29 August 2014 Critical Point

news image

Cutting academic ties with a censured state can do more harm than good, says Mark Peplow